Spots Global Cancer Trial Database for Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Official Title: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
Study ID: NCT05074810
Study Description
Brief Summary: This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Detailed Description: This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety and tolerability and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C mutant NSCLC.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Rocky Mountain Cancer Center, LLP, Boulder, Colorado, United States
Georgetown University Medical Center, Washington, District of Columbia, United States
MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute,, Washington, District of Columbia, United States
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
Maryland Oncology & Hematology, P.A., Rockville, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Henry Ford Health System, Detroit, Michigan, United States
Minnesota Oncology Hematology, P.A, Woodbury, Minnesota, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Ohio State University Brain and Spine Hospital, Columbus, Ohio, United States
Consultants in Medical Oncology & Hematology, Broomall, Pennsylvania, United States
Alliance Cancer Specialists,, Horsham, Pennsylvania, United States
Texas Oncology, Austin, Texas, United States
Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, United States
Texas Oncology, Longview, Texas, United States
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
University Hospital Gent, Gent, , Belgium
CHRU of Lille, Lille, , France
Hôpital Cochin, Paris, , France
Hôpital Foch, Suresnes, , France
Leids Universitair Medisch Centrum, Leiden, , Netherlands
Erasmus MC, Rotterdam, , Netherlands
Hospital Teresa Herrera (C.H.U.A.C), A Coruña, , Spain
Hospital General Universitario Gregorio Marañón, Madrid, , Spain
Hospital Universitario Fundación Jiménez Díaz, Madrid, , Spain
Hospital Universitario Virgen De La Victoria, Málaga, , Spain
Hospital Universitario Virgen de la Macarena, Sevilla, , Spain
University of Leicester, Leicester, , United Kingdom
Royal Marsden Hospital, London, , United Kingdom
Royal Marsden Hospital, Sutton, , United Kingdom
Contact Details
Name: MD Verastem
Affiliation: Verastem, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
